RxDoctor Payments Data

Mohammed Irshad, MD

Gastroenterology · Clinton, IANPI 1508854589

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,439 of the $18,342 with a category attached, or 67.8%. Celltrion USA Inc. accounts for 70.6% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $13,545, 9.7 times the $1,403 reported in 2019. Among gastroenterology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,342in general payments, 2019–2025

Across 163 payments — averaging $112.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Celltrion USA Inc.$13K
  • AbbVie$2K
  • Boston Scientific$661
  • Johnson & Johnson$553
  • Phathom Pharmaceuticals, Inc.$367
  • Takeda Pharmaceuticals U.S.A., Inc.$359
  • plus $2K from 17 others

What the payments were for

  • Speaking & faculty fees$12,43968%
  • Travel & lodging$6203%
  • Food & beverage$5,12628%
  • Education$1561%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,342 in reported general payments places this provider in the 95th percentile of 113 gastroenterology providers in Iowa.

See all gastroenterology providers in Iowa

Medicare billing

Part B allowed, 2024
$92,983
Medicare patients
341
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide11$506,837
StelaraUstekinumab15$400,899
Mesalamine11$14,580
Colesevelam Hcl13$1,099
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$1,023
Pantoprazole Sodium86$576
Omeprazole30$487
Rabeprazole Sodium11$385
Lactulose12$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$359$506,83711 claims
Johnson & JohnsonStelara$553$400,89915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 113 gastroenterology providers in Iowa.

Other gastroenterology in Clinton

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →